natgillin/translations-raw huggingface dataset:
A nucleic acid coding for the polypeptide of any of 1 to 13, particularly a nucleic acid comprising or consisting of a nucleic acid sequence of SEQ ID NO: 26. A vector comprising a nucleic acid molecule according to 14. 
Nukleinska kiselina koja kodira polipeptid sukladno bilo kojem patentnom od zahtjeva 1 do 4, posebno nukleinska kiselina koja sadrži ili se sastoji sekvence nukleinske kiseline iz SEQ ID NO: 26, gdje je navedena nukleinska kiselina opciono sadržana u vektoru.
The compound of Claim 1, wherein R1A is wherein R6A and R7A are both hydrogen, or R6A and R7A are both absent; or R1A is wherein R6A is preferably m is 0, and R7A, R12A and R13A are independently absent or hydrogen, or preferably m is 1, and R7A, R12A, R13A and R14A are independently absent or hydrogen. 
Spoj prema zahtjevu 1, naznačen time što R1A je pri čemu R6A i R7A su oba vodik, ili R6A i R7A su oba odsutni; ili R1A je pri čemu R6A je poželjno m je 0, i R7A, R12A i R13A su neovisno odsutni ili vodik, ili poželjno m je 1, i R7A, R12A, R13A i R14A su neovisno odsutni ili vodik.
In the example shown, supporting shaft 6 is made of stainless steel like the flat plate 5 with which it is integral. 
U prikazanom primjeru, potporna osovina 6 je izrađena od nehrđajućeg čelika kao i ravna ploča 5 s kojom je integralna.
When using the process of the invention, a cyclisation yield of the corresponding linear peptide of formula II, III or IV higher than 70% may be obtained. 
Kada se koristi postupak prema izumu, može se dobiti ciklizacijski prinos odgovarajućih linearnih peptida formule II, TII ili IV veći 70%.
and R3 independently are hydrogen, alkyl or together form an oxo group; 
i R3 su zasebno vodik, alkil ili zajedno formiraju okso grupu;
A medicament comprising as an active ingredient the compound according to any one of claims 1 to 5, or a salt or solvate thereof. 
Medikament, naznačen time što kao aktivni sastojak sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu sol ili solvat.
The soft chewable veterinary composition of claim 1, wherein: the filler is a combination of corn starch and soy protein fines and is present at a concentration of about 30% to about 50% (w/w); the solvent is a mixture of liquid polyethylene glycol and caprylic/capric triglycerides and is present at a concentration of about 5% to about 20% (w/w); 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 1, naznačen time, da: a) punilo je kombinacija kukuruznog škroba i fino mljevenih sojinih proteina i prisutno je u koncentraciji od oko 30% do oko 50% (masa/masa); b) otapalo je mješavina tekućeg polietilenglikola 1 kapriličnih/kapričkih triglicerida 1 prisutno je u koncentraciji od oko 5% do oko 20% (masa/masa):
is H, a straight chain or branched C1-C4 alkyl or a straight chain or branched C1-C4 alkyl substituted by a 5- or 6- membered saturated or unsaturated carbocyclic or heterocyclic ring; 
je H, ravnolančani ili razgranati C1-C4 alkil ili ravnolančani ili razgranati C1-C4 alkil supstituiran s 5- ili 6-članim zasićenim ili nezasićenim karbocikličkim ili heterocikličkim prstenom;
a first closure member (36) which is arranged so as to be vertically movable and is configured to seal the first annular conduit (44); 
prvi dio za zatvaranje (36) organiziran da bude vertikalno pomičan i konfiguriran da zatvara prvi prstenasti vodič (44);
The method as claimed in claim 1, wherein the method further comprises applying a balancing layer on an opposite side of the core, before the applying of heat and pressure, to obtain a balancing layer. 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje metoda dalje sadrži korak nanošenja balansirajućeg sloja (4) na drugu stranu jezgre (3), prije primjene topline 1 pritiska, da bi se dobio balansirajući sloj.
For example the affinity for the oxytocin receptors on the rat uterus may be determined by the procedure of Pettibone et al, Drug Development Research 30. 
Kao primjer, afinitet za oksitocinske receptore na štakorskoj maternici može se odrediti postupkom prema Pettibone i dr.: Drug Development Research, 30, 129-142, (1993.
The process according to any one of claims 1 to 7, wherein the coating of the at least one surface-treated calcium carbonate comprises at least one cationic polymer being a copolymer based on monomer units selected from diallyldialkyl ammonium salts and methacrylic acid and comonomer units selected from the group consisting of acrylamide; methacrylamide; N,N-dimethyl acrylamide; acrylic acid; methacrylic acid; vinylsulfonic acid; vinyl pyrrolidone; hydroxyl ethyl acrylate; styrene; methyl methacrylate; vinyl acetate and mixtures thereof, preferably the monomer units are selected from diallyldialkyl ammonium salts and methacrylic acid and comonomer units selected from acrylamide and acrylic acid. 
Kompozitni materijal prema bilo kojem od zahtjeva 11 do 15, naznačen time da prevlaka najmanje jednog površinski obrađenog kalcijevog karbonata sadrži najmanje jedan kationski polimer koji je kopolimer baziran na monomernim jedinicama koje se biraju od soli dialildialkil amonijaka i ko-monomernim jedinicama koje se biraju iz skupine koju čine akrilamid; metakrilamid; N,N-dimetil akrilamid; akrilna kiselina; metakrilna kiselina; vinilsulfonska kiselina; vinil pirolidon; hidroksil etil akrilat; stiren; metil metakrilat; vinil acetat i njihove smjese.
allowing the antibody or functional part thereof to bind to the amyloid antigen to form an immunological complex; 
omogućavanje antitijelu da se veže za amiloidni antigen tako da se formira imunološki kompleks;
This indicates that 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride behaves as a potent inverse agonist with a high intrinsic activity. 
Ovo znači da se 1-[3-[3-(4-klorfeniDpropoksi]propil]-piperidin monoklorid ponaša kao snažan inverzni agonist s visokim intrinzičnim djelovanjem.
The pharmaceutical composition of claim 13, further comprising an additional cancer therapeutic agent. 
Farmaceutski sastav prema zahtjevu 15, naznačen time, da nadalje obuhvaća jedno dodatno terapeutsko sredstvo.
Preferred embodiments of this invention are characterized by the specification and by the features of claims 2 – 21 of this application as filed, and of pharmaceutical compositions and methods of using these compounds. 
Preferirana ostvarenja ovog izuma karakterizirana su pomoću specifikacije i pomoću karakteristika patentnim zahtjevima 2-20 ove prijave kako je podnešena, i farmaceutskim pripravcima, postupcima, i uporabama ovih spojeva.
In an aspect of the present invention includes a method of increasing patient compliance for treatment of traveler's diarrhea, hepatic encephalopathy, infectious diarrhea, diverticular disease, an antibacterial prophylactic prior to colon surgery, irritable bowel syndrome, Crohn's disease, Clostridum difficile-associated diarrhea, small intestinal bacterial overgrowth, traveler's diarrhea prophylaxis, dysentery, pouchitis, peptic ulcer disease, surgical prophylaxis and gastric dyspepsia by administering once daily dosage form comprising rifaximin. The pharmaceutical composition of the present invention contain, for example, form about 0.1% to 90% of rifaximin. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da je za uporabu u liječenju putnih proljeva, hepatičke encefalopatije, zaraznih proljeva, divertikularne bolesti, za antibakterijsku profilaksu prije operacije debelog crijeva, za liječenje sindroma nadražljivih crijeva, Crohnove bolesti, proljeva uzrokovanog bakterijom Clostridium difficile, prekomjernog broja bakterija u tankom crijevu, za profilaksu putnog proljeva, za liječenje dizenterije, pouchitisa (upale kirurški oblikovane crijevne vrećice), za predoperativnu profilaksu 1 za liječenje želučane dispepsije.
In certain embodiments, the total reaction time of the hydrogenation reaction is for a duration sufficient to reduce the content of the a, B-unsaturated ketone to a level of less than 25 ppm, less than about 15 ppm, less than about 10 ppm, or less than about 5 ppm. 
8. Postupak prema zahljevu 1, naznačen time da hidrogeniranje proizvodi sastav opioidnog analgetika koji ima 20 sadržaj 6, B- nezasićenog ketona manji od 25 ppm, manji od 15 ppm, manji od 10 ppm, ili manji od 5 ppm.
Deuterated drugs have been the subject of a number of patent applications. 
Datum objave prijevoda patentnih zahtjeva: 20.10.2017.
The flue gas purification device according to claim 1, wherein the channel (50) has a deepened bottom extension below said collecting area compared with its first and second sections (50 f, 50 s). The flue gas purification device according to claim 1, wherein the liquid is seawater. 
Uređaj za pročišćavanje dimnih plinova prema zahtjevu 7, naznačen time, da kanal (50) ima udubljenije protezanje dna ispod navedenog sakupljačkog područja, nego što je slučaj u usporedbi s njegovim prvim i drugim odjeljkom (50f, 505).
In another embodiment, the amino acid at heavy chain amino acid position 103 is Valine (V). 
(b) na aminokiselinskoj poziciji 103 jakog lanca, odabire aminokiselina valin (V); i
According to the invention, a sheet- or plate-like body of a composite permanent-magnetic material, preferably an anisotropically oriented one, is engraved and magnetized preferably in a direction substantially perpendicular to the engraved surface of the sheet. 
Sukladno predmetnom izumu, tijelo od kompozitnog permanentno magnetskog materijala u obliku lista ili ploče, a poželjno je s anizotropnomim usmjerenjem, poželjno se ugravira i magnetizira u smjeru koji je u znatnoj mjeri okomit na ugraviranu površinu lista.
The pharmaceutical composition according to claim 1, comprising 125.00 mg of Capecitabine, 3.57 mg of Hypromellose, 37.50 mg of Crospovidone, 89.30 mg of Pharmaburst C, 58.93 mg of Mannitol, 46.82 mg of Microcrystalline Cellulose, 8.22 mg of Magnesium Stearate, 15.54 mg of Aspartame, 3.22 mg of Saccharin Sodium, 7.86 mg of Vanillin, 1.47 mg of Bittermasking Blend and 2.97 mg of Strawberry Flavor. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da sadrži 125,00 mg kapecitabina, 3,57 mg hipromeloze, 37,50 krospovidona, 89,30 farmabursta C, 58,93 mg manitola, 46,82 mg mikrokristalinične celuloze, 8,22 mg magnezij stearata, 15,54 mg aspartama, 3,22 mg natrij saharina, 7,86 mg vanilije, 1,47 mg smjese za maskiranje gorčine i 2,97 mg arome jagode.
An example of a bivalent radical linking two parts of the molecule is Y in formula (I) which links a phenyl to the -(CH2)n-Z moiety. 
Primjer bivalentnih radikala koji povezuju dva dijela molekule je Y u formuli (T) koji povezuje fenil s (CH>)n-Z jedinicom.
A boat according to Claim 6, characterized in that the actuator member (61) is adapted to place the movable element (60, 60A), which is functionally associated with the driven portions (41, 42), in one of the following positions: 
Čamac u skladu s patentnim zahtjevom 6, naznačen time što je aktuatorski element (61) podešen da smjesti pokretni element (60, 60A), funkcionalno povezan s pogonjenim dijelovima (41, 42), u jedan od sljedećih položaja:
Transfected clones were selected and a stably r-hTBP-1 expressing cell line was established. Media 
Transfektirani klonovi su probrani, a stanična linija koja je stabilno eksprimirala r-hTBP-1 je bila uspostavljena.
D-methadone for use according to claim 1, wherein a psychiatric drug to the subject is administered in combination with d-methadone. 
D-metadon za uporabu prema zahtjevu 1, naznačen time što se psihijatrijski lijek daje subjektu u kombinaciji s d-metadonom.
The key blank (and/or key made therefrom, and lock provided therefore) may include one or more of the following features. 
Prazan ključ (i/ili od njega izrađeni ključ i za njega predviđena brava) može uključivati jednu ili više od sljedećih značajki.
The flexible wing (20) of claim 12, wherein each of the plurality of airfoil-shaped profiles (30) is made of a material selected from the group consisting of wood, plastic, resins, composites, carbon materials, and formed sheet metal. 
Fleksibilno krilo (20) prema Zahtjevu 12, gdje je svaki od većeg broja aerodinamično oblikovanih profila (30) izrađen od materijala odabranog iz grupe koja sadrži drvo, plastiku, smole, kompozite, ugljične materijale 1 materijale iz formiranih listova.
In other words, when shouldering the rifle, the shooter exercises a traction on the transmission plate that comprises the springs. 
Drugim riječima, kada se puška osloni na rame, pucač izvrši povlačenje prijenosne ploče koja komprimira opruge.
The formulation according to any of claims 1 to 3 containing the antibody in an amount of at least 50 mg/ml. 
Formulacija prema zahtjevu 3 naznačena time da sadrži protutijelo u količini od barem 50 mg/ml.
or two adjacent R7 substituents together with the atoms to which they are attached form a 4-, 5-, or 6-membered carbocyclic ring or heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N, or S; 
ili dva susjedna R9 supstituenta na aromatskom prstenu su uzeti zajedno da tvore 5 ili 6-čalni prsten koji ima 0-2 heteroatoma odabrani od O, N, i S;
The method of claim 5, wherein the human is resistant to at least one chemotherapeutic agent. The method of claim 5, wherein the chronic lymphocytic leukemia or acute lymphocytic leukemia is refractory CD19+ leukemia. A method of generating a persisting population of genetically engineered T cells in a human diagnosed with cancer, the method comprising administering to the human a T cell genetically engineered to express a CAR wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a costimulatory signaling region comprising 4-1BB, and a CD3 zeta signaling domain comprising the amino acid sequence of SEQ ID NO: 24, wherein the persisting population of genetically engineered T cells persists in the human for at least one month after administration, and wherein the T cell is from a human having cancer. 
T stanica koja je genetski konstruirana tako da eksprimira CAR, naznačena time što CAR sadrži (a) antigen vezujuću domenu koja je anti-CD19 scFv, (b) kostimulatorno signalno područje 4-IBB, i (c) signalnu domenu CD3 zeta za upotrebu u postupku za liječenje raka koji obuhvaća primjenu navedene T stanice kod čovjeka kojem je dijagnosticiran rak, pri čemu anti-CD19 scFv sadrži aminokiselinsku sekvencu prema SEQ ID NO:20 ili signalnu domenu CD3 zeta sadrži aminokiselinsku sekvencu prema SEQ ID NO:24, 1 pri čemu navedeni postupak stvara populaciju genetski konstruiranih T stanica koje perzistiraju u čovjeku najmanje osam mjeseci, devet mjeseci, deset mjeseci, jedanaest mjeseci, dvanaest mjeseci, dvije godine, ili tri godine nakon primjene, i pri čemu je čovjek otporan na liječenje najmanje jednim kemoterapijskim sredstvom.
A method according to claim 17, in which the return of the locking element differs from its lead by the form, especially the amplitude, of the induced voltage spikes in the forward and reverse direction of the locking element. 
Postupak prema jednom od patentnih zahtjeva 15 do 17, naznačen time, da se povratni hod elementa zatvarača(4) razlikuje od njegovog hoda naprijed oblikom, osobito amplitudom vrhova induciranih napona (U1, U2, U3, U4, U5, U6) kod hoda naprijed i povratnog hoda elementa zatvarača (4).
It can be concluded from the above description of the state of art that hitherto there has not been provided any artificial fertilizer that would combine all components needed by the plants and the soil, i.e. 
Iz prikaza ovog poznatog stanja tehnike slijedi da do sada još nije bilo raspoloživo umjetno gnojivo koje bi objedinjavalo sve komponente potrebne biljkama i tlu, to jest organsku komponentu, mineralnu komponentu, biostimulatore i mikroelemente za skupnu aplikaciju.
a fork strap unit (20), said fork strap unit having an upper surface and a lower surface; 
postolja (10), s tim da postolje (10) ima gornju površinu i donju površinu;
A therapeutic nanoparticle for use as a medicament, as claimed in any one of claims 1 to 12, wherein a targeting ligand is additionally present and is PLA-PEG-GL, wherein GL has the following structure: 
Terapijska nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačena time što dodatno sadrži ciljajući ligand, koji je PLA-PEG-GL., gdje GL ima sljedeću strukturu: Å eNH COH
exposing a mouse according to any one of claims 1 to 10 or 17 to an antigen; allowing the mouse to develop an immune response to the antigen; and isolating from the mouse of (b) an antibody that specifically recognizes the antigen, or isolating from the mouse of (b) a cell comprising an immunoglobulin domain that specifically recognizes the antigen, wherein the antibody comprises a heavy chain derived from a human VH gene segment, a human DH gene segment, a human JH gene segment and a mouse CH gene and a light chain derived from a human Vλ gene segment, a human Jλ gene segment and a mouse Ck gene. 
Miš prema zahtjevu 1, naznačen time, što sadrži a) b) 12 humanih V2. segmenata gena; ili 28 ili više humanih VA segmenata gena. Postupak za izradu antitijela u mišu koji se sastoji od a) b) izlaganja miša prema bilo kojem zahtjevu od 1 do 10ili 17 antigenu; puštanja miša da razvije imunološki odgovor na antigen; i izoliranja iz miša (b) antitijela koje specifično prepoznaje antigen ili izoliranja iz miša (b) stanice koja se sastoji od imunoglobulinske domene koja posebno prepoznaje antigen, pri čemu antitijelo sadrži lanac dobiven iz humanog VA segmenta gena, humanog JA segmenta gena i mišjeg CK gena.
To overcome some of these disadvantages beverage containers for dispensing assemblies produced in lighter, more flexible materials have been introduced. 
Da bi se prevladali neki od tih nedostataka uvedeni su spremnici s pićem u sklopovima za točenje pića, koji su proizvedeni iz laganijih, savitljivijih materijala.
The method of claim 38, wherein determining the first plurality of loci includes: determining the paternal genome is homozygous for the respective first allele at each loci of the first plurality and determining the maternal genome is homozygous for the respective second allele at the same locus. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se određivanje prve skupine lokusa sastoji u tome što: za svakog od lokusa iz prve skupine: određivanje očinskog genoma je homozigotno za odgovarajući prvi alel; i određivanje majčinskog genoma je homozigotno za odgovarajući drugi alel.
The method of producing a feed or food product according to claim 3, wherein there is a combination of at least six shutter pieces. 
Postupak proizvodnje krmnog ili prehrambenog proizvoda u skladu s patentnim zahtjevom 2, naznačen time što zatvarač sadrži kombinaciju od najmanje šest dijelova.
The process according to claim 1, wherein the pre-soaking is done for a time less than 48 hours. 
Postupak u skladu s patentnim zahtjevima 1 do 2, naznačen time što se prednamakanje vrši u vremenu kraćem od 48 sati.
A combination of oxycodone hydrochloride and naloxone hydrochloride for use in the treatment of moderate to severe pain in elderly patients, wherein 80 mg up to 160 mg of oxycodone hydrochloride are administered orally per day together with naloxone hydrochloride, wherein the weight ratio of oxycodone hydrochloride:naloxone hydrochloride is 2:1, and wherein oxycodone hydrochloride and naloxone hydrochloride are released in a sustained manner. 
Farmaceutski oblik doziranja s produljenim oslobađanjem koji sadrži 40 mg oksikodona ili njegove farmaceutski prihvatljive soli i 20 mg naloksona ili njegove farmaceutski prihvatljive soli, gdje su oksikodon ili njegova farmaceutski prihvatljiva sol i nalokson ili njegova farmaceutski prihvatljiva sol prisutni u težinskom omjeru od 2:1, za upotrebu u liječenju umjerene do jake boli i opioidom izazvanih sindroma crijevne disfunkcije koji se javljaju tijekom terapije protiv bolova, gdje je navedeni opioidom izazvani sindrom crijevne disfunkcije zatvor, i neželjenih efekata, gdje su navedeni neželjeni efekti tipični naloksonom izazvani neželjeni efekti odabrani iz skupine koja se sastoji od bolova u trbuhu, grčeva i dijareje.
The dsRNA for use of claim 6, wherein the ligand is attached to the 3' end of the sense strand. 
dsRNA prema zahtjevu 1 ili 2, naznačena time da je struktura GalNAc derivata kako je prikazano ispod i vezana je na 3' završetak sensnog lanca dsRNA [image]
However, the results obtained so far, although optimal as far as the product quality is concerned (especially for the steel strips), have turned out to be improvable under the aspect of the lay-out compactness and of the energy saving, as well as of the possible enlargement of the range of flat products that can be obtained. 
Ipak, pokazalo se da se do sada dobiveni rezultati, iako optimalni što se tiče kvalitete proizvoda (posebno za čelične trake), mogu poboljšati u pogledu kompaktnosti postrojenja i uštede energije, kao i mogućeg povećanja asortimana plosnatih proizvoda koji se mogu dobiti.
beer with an EBC colour value of less than 25, more preferably of less than 15, most preferably of less than 12. 
piva s EBC vrijednošću boje manjom od 25, poželjnije manjom od 15, najpoželjnije manjom od 12.
A humanized antibody, or a derived compound or functional fragment of same, characterized in that it comprises heavy and light chains each having i) framework regions homologous to corresponding framework regions of a human antibody, and ii) CDRs homologous to corresponding CDRs of an antibody derived from a different mammalian species, wherein said CDRs consist of CDR-H1, CDR-H2 and CDR-H3 of the heavy chain comprising respectively the sequences SEQ ID Nos. 4, 5 and 6, and CDR-L1, CDR-L2 and CDR-L3 of the light chain comprising respectively the sequences SEQ ID Nos. 7, 8 and 9. 
Humanizirano antitijelo koje se može specifično vezati za CXCR4 ili za njegov funkcionalni fragment, a rečeni funkcionalni fragment odabran je od sljedećih fragmenata: Fv, Fab, (Fab’)2, Fab’, scFv, scFv-Fc te specifična dvostruka antitijela (engl. diabodies), naznačeno time da rečeno humanizirano antitijelo ili izvedeni spoj funkcionalnog fragmenta sadrži teški i laki lanac, a rečeni teški lanac ima CDR koji se sastoje od CDR-H1, CDR-H2 i CDR-H3, a rečeni laki lanac ima CDR koji se sastoje od CDR-L1, CDR-L2 i CDR-L3, gdje rečeni CDR-H1, CDR-H2 i CDR-H3 sadrže odgovarajuće sekvencije SEQ ID br. 4, 5 i 6, a rečeni CDR-L1, CDR-L2 i CDR-L3 sadrže odgovarajuće sekvencije SEQ ID br. 7, 8 i 9.
The compound of claim 1, selected from the group consisting of: 
Spoj u sklađu s patentnim zahtjevom 1, naznačen time što ga so bira iz skupine koju čine:
further comprising a carrier, the carrier being at least one selected from the group consisting of calcium montmorillonite, attapulgite, pumice, perlite, diatomaceous earth, vermiculite, talc and clay. 
nadalje sadrži nosač, - > nosač je barem jedan nosač koji je odabran iz skupine koju čine kalcijev montmorilonit, atapulgit, plovučac, perlit, dijatomejska zemlja, vermikulit, talk 1 glina.
the disorder requiring treatment with the anti-EGFR ADC is cancer; optionally wherein 
Formulacija za uporabu prema zahtjevu 19, naznačena time što poremećaj koji zahtijeva liječenje s anti-EGFR ADC je rak.
The composition of claim 8 further comprising one or more drugs: selected from the group consisting of: anti-IgE antibody, antihistamine, bronchodilator, glucocorticoid, NSAID, TNF-antagonist, integrin antagonist, immunosuppressive agent, IL-4 antagonist, IL-13 antagonist, dual IL-4/IL-13 antagonist, DMARD, antibody that binds to a B-cell surface marker and BAFF antagonist; or 
Sastav prema zahtjevu 13, naznačen time, da nadalje obuhvaća jedan ili više lijekova odabranih iz skupine koju čine: protutijelo anti-IgE, antihistamin, bronhodilator, glukokortikoid, NSAID, TNF-antagonist, integrinski antagonist, imunosupresivno sredstvo, IL-4-antagonist, IL-13-antagonist, dvojni IL-4/IL-13-antagonist, DMARD, protutijelo koje se veže na površinski marker B-stanice i BAFF-antagonist.
The method according to clause 1, wherein the module is prefabricated with dimensions of approximately 6,5 - 7,0 m in length, about 2,5 m in depth, and about 3,0 m in height. 
Postupak sukladno zahtjevu 1, pri čemu je modul (2) prethodno proizveden u dimenzijama otprilike 6,5 - 7,0 m duljine, otprilike 2,5 m dubine, i otprilike 3,0 m visine.